Literature DB >> 2808486

Metastatic human melanoma. Phenotypic heterogeneity and antigen expression in relation to the clinical status.

L Suter1, E B Bröcker, H Ostmeier, J Schumann, C Sorg.   

Abstract

According to animal experiments, metastasis to a particular organ depends on the phenotype of the tumor cells. Widespread metastatic dissemination including internal organs would therefore, at least in part, depend on the capacity of tumor cells to modulate, resulting in increased phenotypic heterogeneity. We found evidence for this assumption in human melanoma by phenotyping metastases (mainly cutaneous/subcutaneous) from 59 patients by the use of six monoclonal antibodies. Interlesional antigenic heterogeneity was present in 22/33 (67%) patients with disseminated metastases including at least one internal organ, but only in 4/26 (15%) patients whose metastases were restricted to skin and/or skin-draining lymph nodes (P less than or equal to 0.01). Chemotherapy cannot be the main reason for interlesional phenotypic heterogeneity, as seen by comparison of treated and untreated patients. Aneuploid melanoma metastases, as an indication for instability on the chromosomal level, were found in the majority of patients (84%) regardless of their clinical situation. Widespread disease was significantly related to the loss of the cytoplasmatic antigen K-1-2 and to the expression of the 130-kDa membrane antigen A-1-43.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808486     DOI: 10.1007/bf00393338

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Organ specificity of blood-borne tumour metastasis determined by cell adhesion?

Authors:  G L Nicolson; J L Winkelhake
Journal:  Nature       Date:  1975-05-15       Impact factor: 49.962

2.  A monoclonal antibody to a formaldehyde-resistant epitope on the nonpolymorphic constant part of the HLA-DR antigens.

Authors:  C Sorg; E B Bröcker; G Zwadlo; K Redmann; U Feige; W Ax; A C Feller
Journal:  Transplantation       Date:  1985-01       Impact factor: 4.939

3.  Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma.

Authors:  S G van Duinen; D J Ruiter; E B Broecker; E A van der Velde; C Sorg; K Welvaart; S Ferrone
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

Review 4.  Mechanisms of tumor progression.

Authors:  P C Nowell
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

Review 5.  Tumor heterogeneity.

Authors:  G H Heppner
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

6.  DNA aneuploidy in congenital melanocytic nevi: suggestive evidence for premalignant changes.

Authors:  W Stenzinger; L Suter; J Schumann
Journal:  J Invest Dermatol       Date:  1984-06       Impact factor: 8.551

7.  Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies.

Authors:  L Suter; E B Bröcker; J Brüggen; D J Ruiter; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 8.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

9.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

10.  The expression of tumor-associated antigens in primary and metastatic human malignant melanoma.

Authors:  J Brüggen; E B Bröcker; L Suter; K Redmann; C Sorg
Journal:  Behring Inst Mitt       Date:  1984-05
View more
  2 in total

1.  The relationship between characteristics of the tumor cells and sex of the patients in primary malignant melanomas.

Authors:  H Ostmeier; J Schumann; F Otto; V Krieg; B Fuchs; B Biess; G Burg; L Suter
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  p-glycoprotein expression in malignant melanoma.

Authors:  B Fuchs; H Ostmeier; L Suter
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.